Can the tablet Udiliv (ursodeoxycholic acid) be administered through a nasogastric (Ryle's) tube?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Udiliv (Ursodeoxycholic Acid) Administration Through Ryle's Tube

Udiliv tablets can be administered through a Ryle's tube (nasogastric tube), but this requires proper preparation and consultation with a pharmacist, as crushing tablets should be avoided whenever possible due to risks of exposure and dosing inaccuracies. 1, 2

Key Considerations for Administration

General Principles for Drug Administration via Enteral Tubes

According to ESPEN guidelines, an enteral tube being used for enteral nutrition can also be used for drug administration if the efficacy of drug administration can be confirmed 1, 2. However, several critical factors must be addressed:

  • Consult the Summary of Product Characteristics for Udiliv to understand the legal position regarding off-label administration through feeding tubes 1
  • Involve a pharmacist in the decision-making process, as they can advise on appropriate preparation methods and suggest alternative formulations if available 1, 2
  • Crushing medicines should be avoided whenever possible due to potential risks of drug exposure to healthcare workers and inaccuracies in drug dosing 2

Practical Administration Protocol

If administration through Ryle's tube is deemed necessary:

  1. Preparation: If no liquid formulation exists, tablets may need to be crushed and suspended in water
  2. Flushing protocol: Flush the tube with at least 30 mL of water before drug administration 1, 2
  3. Individual administration: Administer each medication separately, never mixing multiple drugs together 1
  4. Inter-medication flushing: Flush with 30 mL of water between each medication 1
  5. Post-administration flushing: Flush with at least 30 mL of water after completing drug administration 1, 2

Important Caveats and Pitfalls

Tube occlusion risk: Solid dosage forms have a higher incidence of causing tube blockages, particularly with nasogastric and silicone tubes 1, 2. The small diameter of feeding tubes and protein-rich solutions increase this risk 2.

Bioavailability concerns: The site of drug delivery matters significantly. Ursodeoxycholic acid is primarily absorbed in the small intestine, so gastric administration should maintain efficacy. However, crushing tablets may alter absorption characteristics 1, 2.

Legal responsibility: Using products outside their approved administration route carries additional responsibility that should be accepted prior to prescription, supply, or administration 1, 2.

Equipment Standards

  • Use appropriate ENFit-standard syringes to avoid misconnection errors 1, 2
  • For low-dose ENFit tip syringes, do not shake to remove drug moat, as this exposes the environment to the drug and affects dosing accuracy 1, 2

Clinical Context

While the provided evidence does not contain specific FDA labeling for Udiliv regarding nasogastric administration, the general principles from ESPEN guidelines 1, 2 support that medications can be administered through enteral tubes when properly prepared. The absence of specific contraindications in the available evidence, combined with ursodeoxycholic acid's therapeutic use in hepatobiliary diseases 3, 4, suggests feasibility with appropriate precautions.

The decision to administer Udiliv through a Ryle's tube should involve pharmacist consultation to determine the optimal preparation method, confirm drug stability in suspension, and ensure appropriate dosing accuracy.

References

Guideline

espen guideline on home enteral nutrition.

Clinical Nutrition, 2020

Research

Bile acids in the treatment of hepatobiliary diseases: rational use of UDCA.

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.